Firm
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Sponsored
Sponsored
-
Sponsored by AJ ParkAJ Park explains the key takeaways from a recent case involving trademark disclaimers -
Sponsored by Bird & BirdPeter Brownlow and Mark Hilton of Bird & Bird consider the impact of Brexit on international IP cases heard in England
-
Sponsored by LexOrbisManisha Singh and Simran Bhullar of LexOrbis take a look at the surprising court record of a persistent offender deceptively targeting Indian health and beauty brands
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law summarises the eligible drugs, the re-examination period and strategies available for companies
-
Sponsored by ABE & PartnersTakanori Abe of Abe & Partners previews potential suggested changes to Japan’s patent world
-
Sponsored by MaiwaldEva Ehlich, Angela Zumstein and James Neuhaus of Maiwald note their observations on oral proceedings before the Enlarged Board of Appeal
